Ralph A Tripp

51PUBLICATIONS
20CO-AUTHORS
Proteins and peptidesMajor global burdens of diseaseMedical infection agents (incl. prions)Medical molecular engineering of nucleic acids and proteinsClinical pharmacology and therapeutics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (51)

|Feb 07, 2026
RSV nucleoprotein inhibitors in preclinical to phase II clinical development for respiratory syncytial virus infection.

Ralph A Tripp

|Jan 28, 2026
Evaluation of Probenecid Against Filovirus Replication in Vero E6 Cells.

Kendra Alfson, Ricardo Carrion, Ralph A Tripp

|Nov 27, 2025
Probenecid Treatment Inhibits Replication of the Edmonston Measles Virus Strain in Vero Cells.

Jackelyn Murray, David E Martin, Ralph A Tripp

|Oct 28, 2025
Restricting O-Linked Glycosylation of the Mucin-like Domains Enhances Immunogenicity and Protective Efficacy of a Respiratory Syncytial Virus G Glycoprotein Vaccine Antigen.

Sara M O'Rourke, Jackelyn Murray, Maria G Juarez

|Jul 23, 2025
The MAPK Response to Virus Infection Is Modified by Probenecid.

Les P Jones, David E Martin, Ralph A Tripp

|Apr 30, 2025
Probenecid Inhibits NLRP3 Inflammasome Activity and Mitogen-Activated Protein Kinases (MAPKs).

Les P Jones, David E Martin, Jackelyn Murray

Pageof 9

Frequent Collaborators

14 joint publications

David E Martin

9 joint publications

Harrison C Bergeron

5 joint publications

Kyle V Todd

4 joint publications

Nichole Orr-Burks